Sample Name
Sample Code
Sample Name
Sample Code
Sample Name
Sample Code
4
Ermenegildo Zegna NV
ZGN
5
Halozyme Therapeutics
HALO
(FY)Dec 31, 2024 | (Q4)Dec 31, 2024 | (Q3)Sep 30, 2024 | (Q2)Jun 30, 2024 | (Q1)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q4)Dec 31, 2023 | (Q3)Sep 30, 2023 | (Q2)Jun 30, 2023 | (Q1)Mar 31, 2023 | |
---|---|---|---|---|---|---|---|---|---|---|
Total revenue | 167.35%12.41B | 62.89%3.33B | 145.29%3.54B | 312.81%3.02B | 501.06%2.51B | 843.79%4.64B | 849.32%2.05B | 1.44B | 732.39M | 417.03M |
Operating revenue | 167.35%12.41B | 62.89%3.33B | 145.29%3.54B | 312.81%3.02B | 501.06%2.51B | 843.79%4.64B | 849.32%2.05B | --1.44B | --732.39M | --417.03M |
Cost of revenue | 151.97%6.72B | 53.89%1.78B | 133.33%1.9B | 277.97%1.67B | 436.71%1.37B | 644.21%2.67B | 691.53%1.16B | 816.31M | 441.13M | 256.08M |
Gross profit | 188.18%5.68B | 74.55%1.56B | 160.84%1.64B | 365.57%1.36B | 603.44%1.13B | 1,381.59%1.97B | 1,179.69%891.93M | 627.4M | 291.25M | 160.95M |
Operating expense | 211.43%2.79B | 119.99%914.35M | 222.61%842.29M | 337.50%612.05M | 427.45%426.22M | 260.55%897.44M | 473.92%415.64M | 261.09M | 139.9M | 80.81M |
Selling and administrative expenses | 255.76%2.22B | 140.05%731.97M | 292.64%675.59M | 406.58%484.53M | 534.73%330.21M | 260.79%624.66M | 511.97%304.93M | --172.06M | --95.65M | --52.02M |
-Selling and marketing expense | 406.77%850.46M | 269.65%293.08M | 426.62%280.89M | 671.66%201.26M | 725.15%75.24M | 252.12%167.82M | 424.54%79.28M | --53.34M | --26.08M | --9.12M |
-General and administrative expense | 200.29%1.37B | 94.51%438.89M | 232.45%394.71M | 307.19%283.26M | 494.27%254.98M | 264.09%456.84M | 550.04%225.64M | --118.73M | --69.57M | --42.91M |
Other operating expenses | 109.93%572.62M | 64.74%182.39M | 87.25%166.7M | 188.19%127.53M | 233.55%96.01M | 259.98%272.77M | 389.99%110.71M | --89.02M | --44.25M | --28.78M |
Operating profit | 168.75%2.89B | 34.89%642.48M | 116.82%794.25M | 391.51%743.92M | 780.89%705.94M | 1,027.22%1.07B | 17,591.44%476.29M | 366.32M | 151.36M | 80.14M |
Net non-operating interest income expense | 119.24%37.31M | -109.44%-1.21M | 489.55%21.32M | 2,212.75%7.98M | 4,602.55%9.22M | 788.56%17.02M | 5,771.23%12.86M | 3.62M | 345K | 196K |
Non-operating interest income | 119.24%37.31M | -109.44%-1.21M | 489.55%21.32M | 2,212.75%7.98M | 4,602.55%9.22M | 788.56%17.02M | 5,771.23%12.86M | --3.62M | --345K | --196K |
Other net income (expense) | 239.39%118.19M | 156.04%61M | -253.05%-7.28M | 119.61%35.14M | 791.52%29.34M | -5,584.61%-84.79M | -43,263.35%-108.84M | 4.76M | 16M | 3.29M |
Gain on sale of security | ---- | ---- | ---- | ---- | ---- | ---105.48M | ---- | ---- | ---- | ---- |
Other non- operating income (expenses) | 471.23%118.19M | 1,915.87%61M | -253.05%-7.28M | 119.61%35.14M | 791.52%29.34M | 1,238.36%20.69M | -1,238.25%-3.36M | --4.76M | --16M | --3.29M |
Income before tax | 202.30%3.04B | 84.66%702.26M | 115.72%808.29M | 369.31%787.04M | 790.26%744.5M | 995.47%1.01B | 13,904.28%380.31M | 374.69M | 167.7M | 83.63M |
Income tax | 158.89%527.51M | -17.00%58.13M | 113.80%161.66M | 309.55%158.32M | 667.80%149.4M | 1,040.55%203.76M | 17,857.44%70.03M | 75.61M | 38.66M | 19.46M |
Net income | 213.32%2.51B | 107.60%644.14M | 116.21%646.63M | 387.21%628.72M | 827.40%595.1M | 984.70%802.57M | 9,965.63%310.27M | 299.08M | 129.04M | 64.17M |
Net income continuous Operations | 213.32%2.51B | 107.60%644.14M | 116.21%646.63M | 387.21%628.72M | 827.40%595.1M | 984.70%802.57M | 9,965.63%310.27M | --299.08M | --129.04M | --64.17M |
Minority interest income | -191.58%-1.52M | -1,242.52%-14.89M | 1,470.56%5.65M | 6.87M | 840K | 1.66M | 1.3M | 360K | 0 | 0 |
Net income attributable to the parent company | 214.16%2.52B | 113.30%659.02M | 114.58%640.98M | 381.89%621.85M | 826.09%594.26M | 982.87%800.9M | 9,924.20%308.97M | 298.72M | 129.04M | 64.17M |
Preferred stock dividends | 59.07%51.03M | 15.76%12.76M | 27.62%11.31M | 146.72%15.05M | 95.36%11.92M | 31.48%32.08M | 80.67%11.02M | 8.86M | 6.1M | 6.1M |
Other preferred stock dividends | 325.81%1.03B | 359.36%984.15M | 36.33%15.85M | 88.22%15.32M | 85.63%14.61M | 700.89%241.88M | 2,622.27%214.24M | 11.63M | 8.14M | 7.87M |
Net income attributable to common stockholders | 172.35%1.44B | -503.66%-337.89M | 120.61%613.82M | 415.20%591.48M | 1,031.01%567.73M | 462.62%526.94M | 589.09%83.71M | 278.23M | 114.81M | 50.2M |
Basic earnings per share | 172.35%7.8189 | -503.66%-1.8409 | 120.61%3.3442 | 415.20%3.2225 | 1,031.01%3.0931 | 462.62%2.8708 | 589.09%0.456 | 1.5158 | 0.6255 | 0.2735 |
Diluted earnings per share | 172.35%7.8189 | -503.66%-1.8409 | 120.61%3.3442 | 415.20%3.2225 | 1,031.01%3.0931 | 462.62%2.8708 | 589.09%0.456 | 1.5158 | 0.6255 | 0.2735 |
Dividend per share | ||||||||||
Currency Unit | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY |